Polycystic Kidney Diseases - 25 Studies Found
Completed |
: 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) : Autosomal Dominant Polycystic Kidney Disease : 2011-10-11 :
|
Not yet recruiting |
: A Randomised Feasibility Trial of High Water Intake in Polycystic Kidney Disease : Autosomal Dominant Polycystic Kidney Disease : 2016-09-18 :
|
Completed |
: Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease : Autosomal Dominant Polycystic Kidney Disease : 2006-12-20 :
|
Active, not recruiting |
: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency : Autosomal Dominant Polycystic Kidney Disease : 2011-06-20 :
|
Completed |
: Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) : Autosomal Dominant Polycystic Kidney Disease (ADPKD) : 2006-06-22 :
|
Recruiting |
: The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients : Autosomal Dominant Polycystic Kidney Disease : 2014-04-28 :
|
Recruiting |
: Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease : Polycystic Kidney Disease : 2015-10-30 :
|
Completed |
: Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) : Autosomal Dominant Polycystic Kidney Disease : 2008-09-24 : Other: Water prescription Water prescription in 12 to 16 equally divided doses |
Terminated |
: Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency : Autosomal Dominant Polycystic Kidney Disease (ADPKD) : 2010-10-12 :
|
Completed |
: A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] : Autosomal Dominant Polycystic Kidney Disease : 2009-02-09 : Drug: OPC-41061 orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years. |